Canaccord Genuity Reiterates a 'Buy' on Synta Pharma (SNTA); Ganetespid Update
Tweet
Share
E-mailGet Alerts SNTA Hot Sheet
Price: $0.34 --0%
Rating Summary:
4 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Synta Pharma (NASDAQ: SNTA) price target of $8.00.
Analyst, George Farmer, said, "We reiterate our rating on SNTA shares on our view of ganetespib promise for treatment of non-small cell lung cancer (NSCLC) and potentially other solid tumors."
"The company intends to follow a g-pib regulatory path mirroring that of Xalkori (crizotinib; Pfizer (NYSE: PFE)), which recently won accelerated approval in ALK+ NSCLC on the basis of two single-arm studies showing durable 50% and 61% response rates, respectively. Enrolling SNTA’s trial ex-U.S. (where Xalkori is unavailable), while targeting both chemo-naïve and -experienced patients, should ensure rapid recruitment, in our view."
For an analyst ratings summary and ratings history on Synta Pharma click here. For more ratings news on Synta Pharma click here.
Shares of Synta Pharma closed at $4.96 yesterday.
Analyst, George Farmer, said, "We reiterate our rating on SNTA shares on our view of ganetespib promise for treatment of non-small cell lung cancer (NSCLC) and potentially other solid tumors."
"The company intends to follow a g-pib regulatory path mirroring that of Xalkori (crizotinib; Pfizer (NYSE: PFE)), which recently won accelerated approval in ALK+ NSCLC on the basis of two single-arm studies showing durable 50% and 61% response rates, respectively. Enrolling SNTA’s trial ex-U.S. (where Xalkori is unavailable), while targeting both chemo-naïve and -experienced patients, should ensure rapid recruitment, in our view."
For an analyst ratings summary and ratings history on Synta Pharma click here. For more ratings news on Synta Pharma click here.
Shares of Synta Pharma closed at $4.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
- DA Davidson Reiterates Neutral Rating on Timken (TKR)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
